Houdini Bio, a machine learning-guided DNA sequence design platform, has raised approximately £1.5 million in a pre-seed round led by SCVC, with participation from Deep Science Ventures and the University of Cambridge (Cambridge Enterprise VC). The funding combines non-dilutive grant capital with the oversubscribed equity round. Positioned for rapid commercial scaling ahead of its next funding round, the platform is engineered to overcome the biological barriers that limit genetic medicines by preventing therapeutic DNA from being silenced inside human cells.
Gene and cell therapies are held back by a fundamental biological problem: the human cell frequently mistakes therapeutic DNA for a viral invader. When this happens, the cell activates natural defences that silence the medicine, limiting long-term effectiveness, increasing manufacturing costs and requiring high doses that can trigger dangerous immune reactions. Current industry efforts to keep therapies active rely on trial-and-error experimentation, which is slow, costly and unreliable.
Houdini Bio addresses this at the level of the genetic code itself. By combining machine learning with a mechanistic understanding of cellular defences - specifically the Human Silencing Hub (HUSH) complex, a master silencing mechanism - the platform re-engineers therapeutic DNA sequences to give them a genetic camouflage. This preserves the medical purpose of the therapy while making it undetectable to the cell's defences. Advanced sequence design in the platform reliably boosts gene expression output by more than 10-fold compared to current state-of-the-art methods, enabling therapies to work more efficiently, at lower doses and for longer. Target conditions include blindness, cystic fibrosis, haemophilia, dementia and cancer.
The foundational science originates from two sources. The HUSH complex was originally discovered by Professor Paul Lehner at the University of Cambridge, who identified how the body silences foreign genetic material. Building on this discovery during his PhD in molecular genetics, CEO Jonathan Cohen-Gold identified a novel set of molecular rules that allow certain DNA sequences to escape this cellular shutdown. Houdini Bio has since accelerated these insights using artificial intelligence, creating an engineering platform applicable to gene therapies and cell therapies including CAR-T. The combined funding enabled Houdini Bio to validate its technology and achieve projected technical milestones in a third of the predicted time.
With its platform validated ahead of schedule, Houdini Bio plans to expand its team and scale co-development partnerships with pharmaceutical companies, deep tech innovators and drug pipeline developers seeking to integrate anti-silencing technology.
The industry has made incredible strides, proving genetic medicines can cure previously untreatable diseases, but cellular machinery still rejects these therapies, limiting long term effectiveness and forcing costly, unsafe doses. Our platform introduces a vital shift from trial-and-error screening to repeatable, engineering-driven DNA design. By discovering the molecular rules which allow sequences to escape HUSH, we can rewrite therapeutic DNA to clear cellular checkpoints. We are providing the missing link between these incredible medicines, the market and the patients who need them.
Gene therapies really do represent the future of medicine, but they are stuck behind an invisible commercial and biological bottleneck. Houdini Bio represents the exact type of deep tech infrastructure the ecosystem needs. Solving DNA silencing at the biological root transforms long term efficacy and unit economics, revolutionising the commercial and treatment benefits of gene and cell therapies alike. We are thrilled to back a skilled, ambitious team turning complex biology into a truly usable and scalable solution.
Translating the discovery of the HUSH complex into a predictive engineering toolkit is a massive leap forward for translational biology. Houdini Bio's ability to decipher the rules and mechanisms of HUSH and apply them to synthetic biology resolves a multi-decade challenge in molecular medicine, allowing transgenes to predictably escape host repression for the first time.
